Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Frequently asked questions
What sector does Galera Therapeutics Inc (GRTX) operate in?
Galera Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Galera Therapeutics Inc (GRTX) current stock price?
As of the latest data, Galera Therapeutics Inc stock price is $16.28, with a previous close of $16.70. Galera Therapeutics Inc lost -$0.42 in the last trading session, representing a -2.51% loss.
What is Galera Therapeutics Inc (GRTX) current market capitalization?
Galera Therapeutics Inc market cap is approximately 3.38 billion.
What is Galera Therapeutics Inc (GRTX) Earnings Per Share (EPS)?
The trailing EPS is $120.44.
What is Galera Therapeutics Inc (GRTX) Price-to-Earnings (P/E) ratio?
Galera Therapeutics Inc current P/E ratio is 0.14.
Does Galera Therapeutics Inc (GRTX) pay dividends?
No. Galera Therapeutics Inc does not pay a dividend.
What is Galera Therapeutics Inc (GRTX) beta (volatility) score?
Galera Therapeutics Inc has a beta of 2.605, indicating very high volatility compared to the market.